Details of the Drug
General Information of Drug (ID: DMDWUCX)
Drug Name |
Tetragastrin
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
Trp-Met-Asp-Phe-NH2; CCK 30-33; 3-[[2-[[2-amino-3-(1H-indol-3-yl)propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-[(1-amino-1-oxo-3-phenylpropan-2-yl)amino]-4-oxobutanoic acid; Gastrin tetrapeptide amide; 35144-91-3; Cholecystokinin Fragment 30-33 Amide; AC1N7MCV; GTPL861; GASTRIN I, Fragment 14-17; CHOLECYSTOKININ,Fragment 30-33; L000162; 3-{2-[2-amino-3-(1H-indol-3-yl)propanamido]-4-(methylsulfanyl)butanamido}-3-[(1-carbamoyl-2-phenylethyl)carbamoyl]propanoic acid
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL is unavailable | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 4 | Molecular Weight (mw) | 596.7 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | -2.1 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 16 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 7 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 8 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
|||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | ||||||||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||
References